Rakesh Popat, Haematologist at the University College London Hospitals, Associate Professor at the University College London, shared a post on X:
“In-vivo BCMA CAR-T first in human trial. 3 patients all achieving MRD negativity. This could be revolutionary – no need for lymphodepletion chemo, no complicated cell manufacturing process and better memory T cell phenotype. Looking forward to more data especially safety.”
Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared this post, adding:
“In vivo CAR-T headed for great places in myeloma!
Excellent work by Australian colleagues. The sample size (n)is too small to compare vs Lancet series, but both trials are winners as Rakesh said: no apheresis, no lymphodepletion (LD), and possibly better T-cell fitness since trained ‘in house’.
More data and larger patient numbers (n) needed!”
More updates from ASH25 on OncoDaily.